Core Viewpoint - The inclusion of the HPV vaccine in the national immunization program marks a significant expansion, prioritizing coverage for eligible girls and transitioning the program towards a "lifecycle vaccination" approach [1][5]. Group 1: HPV Vaccine Inclusion and Impact - The HPV vaccine will be a bivalent type, primarily targeting girls of appropriate age, and is expected to be added to the national immunization program within the year [1]. - Cervical cancer is a leading cause of cancer-related deaths among women globally, with China accounting for 23% of cases and 16% of deaths worldwide [2]. - The World Health Organization recommends that member countries include HPV vaccination in their national immunization programs, aiming for 90% of girls to be vaccinated by age 15 [2]. Group 2: Current Vaccination Efforts and Accessibility - As of August, 18 provinces and several cities in China have included HPV vaccination in government initiatives, providing free vaccinations to approximately 60% of eligible girls [3]. - Public awareness and willingness to vaccinate have increased, with 82% of surveyed individuals expressing a desire to vaccinate their daughters against HPV [3]. - The national immunization information system has been fully established, enabling dynamic monitoring of HPV vaccination status [3]. Group 3: Vaccine Development and Cost Reduction - The production and research capabilities for HPV vaccines in China have significantly improved, with two bivalent vaccines approved and widely used [4]. - The price of the bivalent HPV vaccine has decreased dramatically due to provincial centralized procurement, with the lowest bid price now at 27.5 yuan per dose, less than one-tenth of the initial price [4]. Group 4: Future Directions and Strategies - The successful inclusion of the HPV vaccine is expected to enhance the integration of primary and secondary prevention strategies for cervical cancer [5]. - A comprehensive prevention strategy combining vaccination, screening, and early diagnosis is being developed [6]. - Future plans include expanding the types of vaccines in the national immunization program and optimizing existing vaccination protocols based on epidemiological trends and vaccine characteristics [6].

Group 1 - The Chinese government will introduce HPV vaccination services for eligible girls and include the HPV vaccine in the national immunization program, aiming to protect women's health [1][2] - China has a high burden of cervical cancer, with approximately 150,000 new cases and 56,000 deaths reported in 2022, accounting for 23% of global cases, and the incidence rate is rising, particularly among younger populations [1] - The inclusion of the HPV vaccine in the national immunization program is expected to maximize public health benefits and provide free vaccination opportunities for the most vulnerable populations [1][2] Group 2 - Experts have been advocating for the HPV vaccine to be included in the national immunization program to ensure equitable access to vaccination services across different socio-economic conditions [2] - The announcement marks a significant update to China's national immunization program, which has not expanded its vaccine offerings since 2007, and represents the first inclusion of a vaccine targeting a non-communicable disease [2] - This initiative is seen as an important exploration for the public health system, potentially paving the way for a comprehensive immunization program that spans the entire lifecycle [2]

Core Points - The National Immunization Program Expert Advisory Committee has been officially disclosed for the first time since its establishment in 2017, consisting of 30 experts from various fields [1][2] - The committee's role is to ensure independent decision-making based on scientific evidence regarding vaccine safety and efficacy, balancing fiscal and supply-demand considerations [1][2] - The new committee includes an increase of 2 members compared to the previous one, with Wang Junzhi as the chairperson, who has significant experience in vaccine research [2][4] Group 1 - The committee's members come from diverse fields such as epidemiology, microbiology, clinical medicine, health policy, and immunology [2][6] - The committee has previously approved and rejected various vaccination programs based on evidence, indicating a systematic decision-making process [1][2] - The new committee aims to enhance transparency, as this is the first time the member list and working regulations have been publicly shared [2][6] Group 2 - The committee's establishment is seen as a potential opportunity to update the national immunization program, which has not included new vaccines for several years [6][9] - There is a discussion on adjusting the funding model for the immunization program to reduce reliance on government finances, especially in light of declining birth rates [6] - The WHO recommends 10 vaccines for national immunization programs, of which China has not included four, highlighting a gap in vaccine coverage compared to developed countries [7][8]

作者 | 第一财经 吴斯旻 2025.08. 30 本文字数：1681，阅读时长大约3分钟 值得关注的是，新一轮专家咨询委员会包含了5名院士。 我国免疫政策透明度再进一步。 截至目前，国家免疫规划已有17年没有实质性扩容。今年4月，国家疾控局官宣国家免疫规划策略进 入"动态调整优化"阶段。近日，该局首次对外公开国家免疫规划专家咨询委员会（下称"专家咨询委 员会，NIAC"）专家组成员的详细名单，专家数量较此前也有所扩增。受访业界观点认为，此举意味 着"扩免"循证决策的透明度和科学性以及免疫策略动态调整的效率有望优化。 28日，国家疾控局卫生与免疫规划司发布《关于调整国家免疫规划专家咨询委员会委员的通知》 （下称"通知"）。通知提到，根据当前传染病防控、疫苗管理等新形势新要求，结合机构改革、专家 岗位变动、相关部门推荐意见等情况，国家疾控局、国家卫生健康委对专家咨询委员会委员进行了换 届调整，并对章程进行了修订。 根据国家疾控局此次披露，新一届专家咨询委员会由来自流行病学与卫生统计学、病原微生物学、临 床医学、卫生政策与卫生经济学、疫苗学、免疫学、免疫预防实践等相关领域专家组成，任期仍3 年。专家组人数由此前的 ...

Core Viewpoint - The National Immunization Program (NIP) in China is entering a phase of "dynamic adjustment and optimization," aiming to gradually narrow the gap between domestic immunization strategies and international standards while incorporating necessary vaccines [2][4]. Group 1: Transparency and Expert Committee - The National Health Commission has publicly disclosed the detailed list of members of the National Immunization Program Expert Advisory Committee for the first time since its establishment in 2017, increasing transparency and accountability [3][4]. - The new expert committee consists of 30 members, expanded from 27, with expertise in various fields such as epidemiology, clinical medicine, and immunology, ensuring a diverse range of insights [2][4]. - The revised charter emphasizes that committee members must not have direct financial relationships with vaccine license holders, enhancing the independence and impartiality of expert decisions [3][5]. Group 2: Role and Function of the Expert Committee - The core function of the National Immunization Program Expert Advisory Committee is to provide evidence-based recommendations on vaccine usage and immunization strategies, including vaccine introduction, adjustment, and cost-effectiveness assessments [4][5]. - The committee's recommendations are crucial for decisions regarding the inclusion or exclusion of vaccines in the national immunization program, which impacts public health equity and government spending [4][5]. Group 3: Composition and Expertise - The new committee includes five academicians, with notable figures such as Wang Junzhi, who has extensive experience in vaccine regulation and oversight [5][6]. - The committee also features experts with significant contributions to vaccine development and infectious disease management, enhancing its credibility and effectiveness [5][6]. - Suggestions have been made to further improve the committee by adopting international best practices for information disclosure and regular updates on topics, evaluation results, and policy foundations [6].

Core Viewpoint - The HPV vaccine, crucial for preventing cervical cancer in women, is gaining attention in China, with discussions on its inclusion in national immunization programs and local public health initiatives [1][6]. Group 1: Current Policies and Implementation - Sixteen provinces in China have introduced policies for HPV vaccination, with Beijing offering free vaccinations for eligible schoolgirls starting this autumn [2][3]. - The implementation plan in Beijing specifies the use of domestically produced bivalent HPV vaccines for girls aged 9 to 14, following a specific immunization schedule [2]. Group 2: Public Health Impact - HPV infection is responsible for 80-90% of cervical cancer cases, which ranks as the third most common cancer among women aged 15-44 in China [2]. - The call for government-funded vaccinations has been growing, with initiatives already covering over a million eligible girls in Jiangxi province [3]. Group 3: Challenges in Vaccine Accessibility - Economic disparities across regions pose challenges to the expansion of HPV vaccination programs, with approximately 42% of provinces offering free vaccinations [4]. - The average procurement price of HPV vaccines has decreased by 50-70% due to competitive procurement processes, which could enhance accessibility [4][5]. Group 4: Need for National Immunization Inclusion - Experts advocate for the inclusion of the HPV vaccine in the national immunization program to ensure equitable access for all children, regardless of their economic background [6][7]. - The World Health Organization has set a target for 90% vaccination coverage among girls aged 9-14 by 2030, highlighting the urgency for national policy changes [6][7].

无独有偶，国家卫健委副主任、国家疾控局局长沈洪兵在近期举办的2025年疫苗与健康大会上也透 露，国家疾控局准备做一个到2030年的五年规划，逐步缩小国内免疫规划与国际差距，逐步纳入需 要纳入的疫苗。 根据沈洪兵对未来动态调整国家免疫规划的设想：一是新增疫苗的种类。国际普遍共识的、疾病负担 重、成本效益高、疫苗产能满足需求、财政可负担的，要尽快纳入。二是优化现有疫苗免疫程序。根 据流行特点、防控目标变化、疫苗特性等进行优化。三是探索疫苗退出程序。不属于全人群普遍接种 的疫苗，现有疫苗不适应疾病防控需要等情况，也要考虑疫苗退出，或改为储备疫苗。 2025.04. 24 本文字数：2701，阅读时长大约4分钟 作者 | 第一财经 吴斯旻 我国国家免疫规划已有17年没有纳入新疫苗。时值"世界免疫周"，国家疾控局近日频频发声，释放 出国家免疫规划策略将"动态调整""提质扩容"的信号。多名受访业界人士认为，国家免疫规划疫苗扩 容优化已至关键节点。 国家疾控局卫生免疫司副司长李筱翠近日在国家疾控局召开的一场新闻发布会上介绍说，当前，传染 病仍然是全球面临的公共卫生风险，需要我们不断加强疫苗接种的普及和推广。为此，在当前和今 ...